| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sonoma Pharmaceuticals, Inc.$1.22
0 (0%)
D 31Pipeline Score MedTech · Clinical
Market Cap
3.82 M
EPS
-2.04
P/E Ratio
-
Value Trade
378.91 K
SEC Financials
Q1 2026Dilution Risk
Revenue
5.56 M
R&D Expenses
545.00 K
Operating CF
-983.00 K
Total Assets
13.96 M
Total Liabilities
10.87 M
Equity
3.10 M
D/E Ratio
12,345
-7.56 %
Week
-53.59 %
1 Month
-61.27 %
3 Month
-66.26 %
6 Month
-99.25 %
5 Year
-100 %
All Time
Cash Data
Cash Position
2.40 M
Monthly Burn
328.00 K
Runway
6.4 mo
Burn Trend
SEC Filing
Jun 16, 2026
Overview
Volume
10.91 K
52 Week Range
0.85 - 6.92
% held by Insiders
0.44 %
% held by Institutions
1.43 %
Enterprise Value
1.91 M
Total Shares
3.47 M
Short %
1.74 %
Float Shares
3.43 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sonoma Pharmaceuticals, Inc.
301Total events
0Upcoming
66Tier-1 (high impact)
2007 – 2026Coverage
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●Management ChangeCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D31
Pipeline Score $9M
Pipeline ValueValuation Signal
3
Drugs Scored2.5x
rNPV / MCap Top 37%
Micro Cap (rank 576 of 912)
Percentile RankSonoma Pharmaceuticals, Inc. faces pipeline headwinds (31/100), with $998M risk-adjusted pipeline value, led by Dermacyn in Foot Ulcer, Diabetic (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermacyn Small molecule | Foot Ulcer, Diabetic | Phase 2 | NCT00516958 | 23% | $780M | COMPLETED | 65 | - | - | Dec 1, 2007 | - | Jan 14, 2008 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SNOA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SNOA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SNOASonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
Sonoma Pharmaceuticals has received FDA 510(k) clearance for its Microdacyn Wound Irrigation Solution, allowing for expanded claims and multiple-use applications. The new clearance includes various packaging options, enhancing the product's marketability. CEO Amy Trombly highlighted the strategic importance of this clearance for growth and partnerships in the wound care sector.
Read more →SNOASonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Sonoma Pharmaceuticals reported strong financial results for fiscal year 2026, with a 48% increase in Q4 revenues compared to the previous year. The company also noted a significant improvement in net loss and EBITDA loss. Despite some regional declines in revenue, Sonoma continues to expand its product offerings and distribution networks, focusing on strategic growth and operational efficiency.
Read more →SNOASonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
Sonoma Pharmaceuticals reported a 22% revenue increase for Q3 2026, with a 33% rise for the nine months ending December 31, 2025. The company also noted a decrease in net loss and EBITDAS loss, reflecting improved financial performance. Key developments included successful FDA registration of a manufacturing facility and new product launches, alongside leadership changes to enhance governance.
Read more →SNOASonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
Sonoma Pharmaceuticals has appointed Vanessa Jacoby and Arturo Angel to its Board of Directors and as Senior Vice President, respectively. Jacoby brings extensive financial and biotech experience, while Angel has a strong background in product development. The company also announced the retirement of Dr. Jay Birnbaum, who has been a significant contributor since 2007.
Read more →SNOA▼ -6%on this news
Sonoma Pharmaceuticals, Inc. Investor Presentation January 2026 Legal Disclaimers r INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all
Sonoma Pharmaceuticals, Inc. presented an investor communication outlining its capabilities and future outlook, including its patented Microcyn technology. The presentation emphasized the company's global footprint, with over 20 years in the development of stabilized hypochlorous acid products. It also highlighted recent expansions in distribution partnerships, including relationships with Medline Industries. The company boasts robust clinical evidence supporting the efficacy and safety of its products in various healthcare applications.
Read more →SNOASonoma Pharmaceuticals, Inc. Investor Presentation September 2025 Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be
Sonoma Pharmaceuticals, Inc. provided an investor presentation detailing its advancements and regulatory achievements as a leader in hypochlorous acid products. The presentation highlights the company's patented Microcyn technology, which is clinically proven for safety and efficacy in various healthcare applications. Despite its successes, Sonoma acknowledges inherent risks associated with regulatory compliance and market penetration challenges. The company is actively expanding its product lines and distribution partnerships, particularly focusing on wound care solutions in the U.S. and internationally.
Read more →SNOA▼ -6.9%on this news
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2025 1 Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be al
Sonoma Pharmaceuticals, Inc. presented an update on its business strategies and product offerings, highlighting its commitment to developing hypochlorous acid (HOCl) products for various healthcare applications. Recent partnerships and a strong regulatory portfolio were emphasized, alongside the effectiveness and safety of its Microcyn technology. Despite the optimistic outlook, the company also acknowledged potential market risks and challenges in achieving regulatory approvals. The focus remains on expanding its reach in the global healthcare market, with ongoing product innovations and collaborations.
Read more →SNOA▼ -5.4%on this news
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2025 Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all
Sonoma Pharmaceuticals, Inc. recently presented an investor communication outlining its business operations and future outlook. The company's products leverage patented Microcyn technology, showing efficacy in various medical applications, including wound and dermatological care. However, the presentation also highlighted inherent risks associated with forward-looking statements, such as potential regulatory hurdles and market competition. Additionally, Sonoma emphasized its extensive regulatory portfolio and partnerships that support its global market presence.
Read more →SNOASonoma Pharmaceuticals, Inc. Investor Presentation October 2024 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all -
Sonoma Pharmaceuticals, Inc. recently highlighted its ongoing developments in its investor presentation for October 2024. The company continues to make strides in the hypochlorous acid market, supported by an extensive regulatory portfolio and a diverse application of their products. New distribution agreements have been established, particularly with Medline Industries for U.S. and Canadian markets. However, Sonoma acknowledges inherent risks associated with forward-looking statements, including regulatory developments and market competition, which may influence their financial performance.
Read more →SNOA▼ -25%on this news· ran to -35% by day 3
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock
Sonoma Pharmaceuticals announced a 1-for-20 reverse stock split effective August 29, 2024. The decision, backed by stockholder approval, aims to bolster the company's stock price for continued compliance with Nasdaq's listing requirements. Notably, each twenty shares will convert into one share, reducing the total from approximately 20 million to 1 million shares outstanding. The split underscores potential financial challenges, as maintaining the Nasdaq listing could be pivotal for the company's investment credibility.
Read more →SNOA▲ +6.3%on this news· ran to +19% by day 3
Sonoma Pharmaceuticals, Inc. Investor Presentation
Sonoma Pharmaceuticals, Inc. presented key insights into its operations and technological advancements in its recent investor presentation. The company specializes in stabilized hypochlorous acid products, which are utilized across various healthcare sectors, including dermatology, wound care, and disinfectants. Despite demonstrating strong performance and safety records, potential risks related to regulatory developments and market competition were acknowledged, indicating that future growth may be uncertain. Sonoma's extensive global distribution network and proprietary technology position it well in the healthcare market.
Read more →SNOA▼ -5.4%on this news
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2024 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - i
Sonoma Pharmaceuticals, Inc. held an investor presentation in April 2024 to discuss its advancements and offerings in healthcare products featuring stabilized hypochlorous acid (HOCl). The presentation emphasized the company's extensive regulatory accomplishments, including multiple FDA clearances and its global reach, distributing products in over 55 countries. The firm also highlighted the safety and efficacy of its products, which cater to a variety of medical fields such as dermatology, wound care, and animal health. Despite the optimistic outlook presented, no specific risks were identified in this communication.
Read more →SNOA▲ +13%on this news· ran to +26% by day 1
Sonoma Pharmaceuticals, Inc. Investor Presentation January 2024 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all -
Sonoma Pharmaceuticals, Inc. provided an investor presentation highlighting its advancements in hypochlorous acid products. The presentation underscores the company’s leadership in wound care and dermatological solutions with a proven safety profile. However, it also outlines several risks associated with future performance, including regulatory hurdles and market penetration challenges. Sonoma operates a state-of-the-art facility in Mexico, emphasizing its commitment to innovation and an extensive global partner network.
Read more →SNOASonoma Pharmaceuticals, Inc. Investor Presentation October 2023 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all -
Sonoma Pharmaceuticals, Inc. has presented an investor update outlining its progress and strategic direction. The company focuses on developing stabilized hypochlorous acid products shown to have therapeutic benefits across various medical and consumer applications. With over 20 years in the industry, Sonoma has established a significant footprint with numerous patents and regulatory approvals. However, challenges related to market competition and the uncertainties surrounding future performance were also highlighted in the presentation.
Read more →SNOASonoma Pharmaceuticals, Inc. May 2023 1 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data co
Sonoma Pharmaceuticals, Inc. provided an investor presentation that outlined its diverse healthcare portfolio and its advancements in stabilized hypochlorous acid (HOCl) products. The company emphasized its history of FDA clearances and the potential to expand into lucrative markets such as dermatology and wound care. While Sonoma has established a robust international distribution network, it acknowledged various risks including regulatory uncertainties and financial constraints. The presentation also highlighted recent partnerships to enhance sales and product distribution across multiple regions.
Read more →SNOASonoma Pharmaceuticals, Inc. January 202 3 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data
Sonoma Pharmaceuticals, Inc. has presented its latest developments and market opportunities in a recent investor presentation. Notably, the company launched two new dermatological products in January 2023 and is actively expanding its product distribution both domestically and internationally. While the presentation highlights strong clinical efficacy for its products, it acknowledges inherent risks related to regulatory approvals and market competition. The company aims to capitalize on growing markets, especially in the healthcare sector focused on non-toxic skin care solutions.
Read more →SNOASonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2022 1 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclus
Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2022 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various inter
Read more →SNOASonoma Pharmaceuticals, Inc. NASDAQ: SNOA March 2021 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive.
Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA March 2021 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various interna
Read more →SNOASonoma Hills Farm Announces Farmer’s Reserve Collection: Limited Edition, Premium Strains Packaged in All-in-One Flower & Glass Pipe Combo
Petaluma, CA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sonoma Hills Farm, a premium craft cannabis farm and culinary garden located in Sonoma County, has announced its newest product offering: the Farmer’s Reserve Collection. Sourced from the farm’s most unique genetics, these limited
Read more →SNOASonoma Pharmaceuticals, Inc.: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA) investors that the firm has initiated an
Read more →SNOASonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2021 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusiv
Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2021 Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various inter
Read more →SNOASONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) on behalf of Sonoma stockholders. Our investigation concerns whether
Read more →SNOASonoma Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, Nov. 25, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ:SNOA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of inves
Read more →SNOASonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group
Sonoma Pharmaceuticals has finalized an asset purchase agreement with MicroSafe Group for $1.1 million, covering wound care and disinfectant products in the Middle East, Australia, and Europe. This partnership aims to enhance the distribution of Sonoma's Microcyn® Technology, which has proven beneficial for patients with chronic skin conditions. The agreement allows MicroSafe exclusive distribution rights for a decade.
Read more →SNOASonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results
Sonoma Pharmaceuticals reported its third quarter financial results for FY 2020, showing a total revenue of $4.68 million, an 11% decrease from the previous year. The company is approaching break-even status, with significant reductions in operating expenses due to cost-saving measures. However, product revenues in the U.S. have declined, impacting overall financial performance.
Read more →SNOASonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division
Sonoma Pharmaceuticals has engaged Maxim Group LLC to explore strategic opportunities for its U.S. Dermatology Division. The company aims to maximize the value of its dermatology products, which have been beneficial for millions of patients. However, there is no set timeline for any potential transactions, and uncertainties remain regarding market dynamics.
Read more →SNOASonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock
Sonoma Pharmaceuticals has successfully closed a public offering of 446,577 shares of common stock at $3.50 per share, raising approximately $1.4 million in net proceeds. The funds will primarily support general working capital, including marketing and product development. Dawson James Securities acted as the lead placement agent for this offering.
Read more →SNOASonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock
Sonoma Pharmaceuticals has announced the pricing of a public offering of common stock at $3.50 per share, aiming to raise approximately $1.6 million. The offering is expected to close around November 29, 2019, pending regulatory approval. The proceeds will be used for general corporate and working capital purposes.
Read more →SNOASonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock
Sonoma Pharmaceuticals, Inc. has announced a public offering of its common stock, facilitated by Dawson James Securities, Inc. The company plans to utilize the proceeds for general corporate purposes, including marketing and product development. This offering is conducted under an effective shelf registration statement filed with the SEC.
Read more →SNOASonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results
Quarterly and YTD Reduction in Net Loss Compared to Prior Year PETALUMA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated ther
Read more →SNOASonoma Pharmaceuticals Announces Management Changes
Sonoma Pharmaceuticals has announced significant management changes, appointing Amy Trombly as Interim CEO and John Dal Poggetto as CFO. Bubba Sandford, who served as CEO and Interim CFO, has left the company but will remain on the Board for six months. The Board is actively searching for a new CEO with industry experience.
Read more →SNOASonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results
Strong Quarter-Over-Quarter Performance 26% Increase in U.S. Product Revenue 46% Increase in Dermatology Revenue 23% Reduction in Operating Expenses PETALUMA, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical com
Read more →SNOASonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule
Sonoma Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price rule, following a reverse stock split. The company received a formal determination letter from Nasdaq confirming that its stock price has exceeded the required $1.00 minimum for continued listing. Sonoma specializes in developing therapies for chronic skin conditions and aims to improve patient care.
Read more →SNOASonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results
Strong Annual Year-Over-Year Growth with 14% Revenue Growth Strong Quarter-Over-Quarter Growth with 20% Revenue Growth and 25% Reduction in Expenses Reduction in Annual Year-Over-Year Net Loss by 18% PETALUMA, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, I
Read more →SNOASonoma Pharmaceuticals Announces 1-for-9 Reverse Split of Outstanding Common Stock
PETALUMA, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the timing for a 1-for-9 reverse split of its outstanding common stock which will be effected on June 19, 2019 at 5:00 pm EDT. Sonoma
Read more →SNOASonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for $2.7 million
PETALUMA, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the sale of certain animal health product rights and assets for the Asian and European markets to Petagon, Limited, an international im
Read more →SNOASonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures
PETALUMA, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced substantial cost-cutting measures, including reductions to the company’s workforce and management. The measures come on the heels of
Read more →SNOADan K. Turner, III
Montreux Equity Partners San Francisco, CA 94111 Sent via Email and U.S. Post Office We are in receipt of your two letters. We value all of our shareholders, both large and small, and respect your input. We have taken your concerns seriously. Our Lead Independent Director rea
Read more →SNOASonoma Pharmaceuticals Announces Pricing of Public Offering of Units
PETALUMA, Calif., Nov. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of a “best efforts” public offering of units consisting of one share of common stock, together with one half of one warrant to purchase one share of common
Read more →SNOASonoma Pharmaceuticals Reports Record Revenue in Second Quarter FY 2019
• Total Revenue of $4.9 Million, up 13% over June 2018 Quarter • Total Revenue up 14% over September 2017 Quarter Conference Call Begins at 4:30 pm EST Today PETALUMA, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced financ
Read more →SNOASonoma Pharmaceuticals Reports Record Revenue in Second Quarter FY 2019 Total Revenue of $4.9 Million, up 13% over June 2018 Quarter Total Revenue up 14% over September 2017 Quarter Conference Call
Sonoma Pharmaceuticals Reports Record Revenue in Second Quarter FY 2019 Total Revenue of $4.9 Million, up 13% over June 2018 Quarter Total Revenue up 14% over September 2017 Quarter Conference Call Begins at 4:30 PETALUMA, CA-(November 8, 2018) -Sonoma Pharmaceuticals, Inc.
Read more →SNOASonoma Pharmaceuticals Announces Second Quarter FY 2019 Financial Results and Conference Call
PETALUMA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced that financial results for its fiscal year 2019 second quarter, ended September 30, 2018, will be released after the U.S. markets close on November 8, 2018. The earnin
Read more →SNOASonoma Pharmaceuticals Announces Newly Published Results from Study of Hypochlorous Acid in Management of Hypertrophic and Keloid Scars
PETALUMA, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced newly published results from a study into the use of the company’s proprietary Performance Stabilized HOClTM (hypochlorous acid) for the management of scars. The newly
Read more →SNOASonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™
PETALUMA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced th
Read more →SNOASonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.
PETALUMA, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced i
Read more →SNOASonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
PETALUMA, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the appointment of Philippe Weigerstorfer to the company’s board of directors. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma’s b
Read more →SNOASonoma Pharmaceuticals Announces Results from Study of Sonoma’s Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris
PETALUMA, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced that results from a study into the use of the company’s proprietary high-strength Performance-Stabilized HOClTM in the management of acne vulgaris were presented at th
Read more →SNOASonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results
Total Revenue up 20% over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced financial results for the first
Read more →SNOASonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results Total Revenue up 20% over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Conference Call Begins at 4:30pm EDT T
Pharmaceuticals Reports First Quarter FY 2019 Financial Results Total Revenue up 20% over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Call Begins at 4:30pm EDT Today PETALUMA, CA-(August 8, 2018) -Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announce
Read more →SNOASonoma Pharmaceuticals Announces First Quarter FY 2019 Financial Results and Conference Call
PETALUMA, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) today announced that financial results for its fiscal year 2019 first quarter, ended June 30, 2018, will be released after the U.S. markets close on August 8, 2018. The earnings release
Read more →SNOASonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results Strong Annual Year-Over-Year Growth in Revenue of 30% $10 Million in Cash as of
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results Strong Annual Year-Over-Year Growth in $10 Million in Cash as of March Conference Call Begins at 4:30pm PETALUMA, Calif.-(June 13, 2018)-Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a speci
Read more →SNOASonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results
Strong Annual Year-Over-Year Growth in Revenue of 30% $10 Million in Cash as of March 31, 2018 Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that de
Read more →SNOASonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), today announced that financial results for its fiscal fourth quarter 2018, ended March 31, 2018, will be released after the U.S. markets close on June 13, 2018. The earnings release wi
Read more →SNOASonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer
PETALUMA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that develops and markets unique and effective dermatological solutions, announced today that Marc Umscheid has been promoted to chief operating offic
Read more →SNOASonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
PETALUMA, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, t
Read more →SNOASonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel
PETALUMA, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for management of dermatological conditions and advanced tissue care, toda
Read more →SNOASonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution
PETALUMA, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, t
Read more →SNOASonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018
PETALUMA, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants – SNOAW) today announced that Jim Schutz, Sonoma CEO, will be a featured presenter at the Roth Capital Partners 30th Annual Growth Stock Conference on Tuesday, March 13, 2018
Read more →SNOASonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock
PETALUMA, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants – SNOAW) today announced the closing of a public offering of 1,428,570 shares of common stock at a public offering price of $3.50 per share. The net proceeds to Sonoma Pharm
Read more →SNOASonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock
PETALUMA, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants – SNOAW) today announced the pricing of a “best efforts” public offering of up to 1,428,571 shares of common stock at a public offering price of $3.50 per share. The gross p
Read more →SNOASonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% Product revenue up 12% compared to September 2017 quar
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth Conference Call Begins at 4:30pm EST Slide Presentation to Review in Tandem with Earnings Call Available at http://ir.sonomapharma.com/eve
Read more →SNOASonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%
Product revenue up 12% compared to September 2017 quarter U.S. product revenue up 27% compared to the September 2017 quarter Cash on hand equals $8.6 million at quarter end Conference Call Begins at 4:30pm EST Today Slide Presentation to Review in Tandem with Earnings Call Av
Read more →SNOASonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW) today announced that financial results for its fiscal third quarter 2018, ended December 31, 2017, will be released after the U.S. markets close on February 7, 2018. Th
Read more →SNOASonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn for Management of Blepharitis, Microsafe Oral Care for Mucositis and Sinudox for Chronic Sinusitis
PETALUMA, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, to
Read more →SNOASonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis
PETALUMA, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, to
Read more →SNOASonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
PETALUMA, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, to
Read more →SNOASonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million Product revenue up 15%, compared to the June 2017 q
Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of Conference Call Begins at 4:30pm Slide Presentation to Review in Tandem with Earnings Call Available at http://ir.sonomapharma.com/events.cfm PETALUM
Read more →SNOASonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million
Product revenue up 15%, compared to the June 2017 quarter Prescriptions filled were up 42% over last year and up 14% over the June 2017 quarter to 19,660 EBITDA loss reduced to $2.3 million Cash on hand equals $10 million Conference Call Begins at 4:30pm EST Today Slide Pres
Read more →SNOASonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products
Brazilian Ministério da Saúde Approves Marketing of Sonoma Pharmaceuticals’ Products: Lasercyn™, Gramaderm®, Epicyn™ and Pediacyn™ Brazilian Dermatology Market Second Largest in the World Behind the United States PETALUMA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharma
Read more →SNOASonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that financial results for its fiscal second quarter 2018, ended September 30, 2017, will be released after the U.S. markets close on November 9, 2017.
Read more →SNOASonoma Pharmaceuticals Announces U.S. Commercialization of Loyon for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
PETALUMA, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, to
Read more →SNOASonoma Pharmaceuticals Announces Commercialization of MicrocynAH Animal Healthcare Products in Japan
PETALUMA, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, t
Read more →SNOASonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. derma
Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. dermatology sales Conference Call Begins at 4:30pm PETALUMA, Calif.-(August 8, 2017
Read more →SNOASonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018
Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. dermatology sales Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW)
Read more →SNOASonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal first quarter 2018, ended June 30, 2017, will be released after the U.S. markets close on August 8, 2017. Th
Read more →SNOASonoma Pharmaceuticals Announces Record Quarterly Prescription Data
Quarter ended June 30, 2017: Highest quarterly number of prescriptions filled 24% up over prior March quarter 2017 46% up over June quarter 2016 PETALUMA, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ:OCLS) (OCLSW), a specialty pharmaceutical c
Read more →SNOASonoma Pharmaceuticals Announces Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact on Post-Procedure Treatment and Scar Prevention
PETALUMA, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- A distinguished panel of U.S. dermatologists and plastic surgeons explored current literature to establish the value of hypochlorous acid (HOCl) as both a pre- and post-procedure regime aimed at prevention of infection, reductio
Read more →SNOASonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars
PETALUMA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, to
Read more →SNOASonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017
Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by growth in U.S. dermatology sales Cash position of $17.5 million; management believes the company is more than fully funded to achieve EBITDA breakeven Conference Call Beg
Read more →SNOASonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017 Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by g
Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017 Conference Call Begins at 4:30pm PETALUMA, Calif.-(June 5, 2017)-Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique a
Read more →SNOASonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2017 Financial Results and Conference Call
PETALUMA, Calif., June 02, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal year and fourth quarter 2017, ended March 31, 2017, will be released after the U.S. markets close on June 5,
Read more →SNOASonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn for Atopic Dermatitis and Epicyn for Scar Management
PETALUMA, Calif., April 12, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, t
Read more →SNOASonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon Skin Descaler for Relief of Scaling Associated with Various Dermatoses
PETALUMA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, t
Read more →SNOASonoma Pharmaceuticals Receives Final $1.5 Million Payment From Sale of Latin America Business to Invekra S.A.P.I. de C.V.
PETALUMA, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, t
Read more →SNOASonoma Pharmaceuticals Announces Results from SebuDerm™ Gel Study in Treatment of Seborrheic Dermatitis
Evaluation of SebuDerm (hypochlorous acid) Gel on Mild to Moderate Facial and Scalp Seborrheic Dermatitis Investigator Global Assessment (IGA) Scores Showed a 33% Improvement at Day 14 and a 52% Improvement at Day 28 Clinical Poster being Presented at the 13th Annual Maui Derma
Read more →SNOASonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology Sales Cash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of $15.5 Million and Net Income of $16.2 Million Due to the Sale of Latin America Asset
Read more →SNOASonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017 U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology Sales Cash Position of $20.5 Million; More Than Fully
Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017 Conference Call Begins at 4:30pm PETALUMA, Calif.-(February 9, 2017)-Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and eff
Read more →SNOASonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer
PETALUMA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced the appointment of Marc Umscheid as chief strategy and marketing officer. Previously, Umscheid worked at the Clorox Company where he most recently serv
Read more →SNOASonoma Pharmaceuticals Announces Fiscal Third Quarter 2017 Financial Results and Conference Call
PETALUMA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal third quarter 2017, ended December 31, 2016, will be released after the U.S. markets close on February 9, 201
Read more →SNOAOculus Innovative Sciences Reports Financial Results for Fiscal Second Quarter 2017 U.S. Product Revenue up 43%, Driven by Growth in U.S. Dermatology Oculus Announced Sale of Latin America Assets fo
Innovative Sciences Reports Financial Results for Fiscal Second Quarter 2017 Conference Call Begins at 4:30pm PETALUMA, Calif.-(November 10, 2016)-Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets uniq
Read more →SNOAOculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017 Product Revenue Up 20% Driven by Growth in U.S. Dermatology Dermatology Prescriptions Up 37%, June Quarter
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017 Conference Call Begins at 4:30pm PETALUMA, Calif.-(July 28, 2016)-Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and m
Read more →SNOAOculus Innovative Sciences Reports Financial Results for Fiscal Year 2016 and Fourth Quarter Ending
Oculus Innovative Sciences Reports Financial Results for Fiscal Year 2016 and Fourth Quarter Ending March 31, 2016 Product Revenue for Fiscal Year 2016 Grew 31% Led by Growth in U.S. Dermatology Conference Call Begins at 4:30pm PETALUMA, Calif.-(June 16, 2016)-Oculus Innovat
Read more →SNOAOculus Innovative Sciences Announces Proposed Underwritten Public Offering of Common Stock and Warrants PETALUMA, Calif.-(
Oculus Innovative Sciences Announces Proposed Underwritten Public Offering of Common Stock and Warrants PETALUMA, Calif.-(March 17, 2016)-Oculus Innovative Sciences, Inc. (NASDAQ: Common Stock - OCLS, Warrants - OCLSW) today announced that it intends to offer and sell, subject
Read more →SNOAOculus Innovative Sciences Reports Third Quarter Financial Results U.S. Dermatology and Rest of the World Sales Drive Product Revenue Growth of 40% Conference Call at 4:30pm ET Today PETALUMA, Calif
Innovative Sciences Reports Third Quarter Financial Results U.S. Dermatology and Rest of the World Sales Drive Product Revenue Growth of 40% Conference Call at 4:30pm ET Today PETALUMA, Calif.--(February 4, 2016)--Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLS
Read more →SNOAOculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2016 Total Revenue of $4.1 Million Increased 24%-Led by 64% Increase in Product Revenue-Driven by Growth in
Oculus Innovative Sciences Reports Financial for the Second Quarter of Fiscal Year 2016 Total Revenue of $4.1 Million Increased 24%-Led by 64% Increase in Product Revenue-Driven by Growth in U.S. Dermatology Sales Conference Call at 4:30 pm ET PETALUMA, Calif.--(November 5,
Read more →SNOAInvestor Presentation At Dawson James Investor Conference
Investor Presentation At Dawson James Investor Conference October 15, 2015 (NASDAQ: OCLS & OCLSW) This presentation includes forward - looking statements that are made pursuant to the "safe harbor " provisions of the Private Securities Litigation Reform Act of 1995 . While these
Read more →SNOAOculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016 U.S. dermatology and Latin American sales drive 37% product revenue growth FDA 510k clearance for treat
Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016 Conference call begins at 4:30 p.m. EDT today PETALUMA, Calif.--(July 30, 2015)--Oculus Innovative Sciences, Inc. (NASDAQ: common stock OCLS, tradeable warrants OCLSW) today announc
Read more →SNOAOculus Innovative Sciences Reports Financial Results for the Fourth Quarter of Fiscal Year 2015 Total revenue increased 37% to $4 million from $2.9 million in the same period last year; up 25% from
Oculus Innovative Sciences Reports Financial Results for the Fourth Quarter of Fiscal Year 2015 PETALUMA, Calif.--(June 11, 2015)--Oculus Innovative Sciences, Inc. (NASDAQ: common stock OCLS, tradable warrants OCLSW) today announced financial results for the fourth quarter of
Read more →SNOAOculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015 Total revenue of $3.3 million for the second quarter Net loss of $718,000, reduced from $1.4 million i
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015 Conference Call Begins at 4:30 p.m. (ET) PETALUMA, Calif.--(November 13, 2014)--Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced financial results for the second qua
Read more →SNOAOculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015 Net loss of $70,000, reduced $1.6 million from same period last year Oculus owns
Oculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015 Conference Call Begins at 4:30 p.m. PETALUMA, Calif.--(August 7, 2014)--Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced financial results for t
Read more →SNOAOculus Innovative Sciences Reports Revenues of $2.9 Million and Net Income of $7.5 Million for Fourth Quarter of Fiscal 2014 Primarily Due to Accounting Treatment of Ruthigen IPO Transaction Oculus'
Oculus Innovative Sciences Reports Revenues of $2.9 Million and Net Income of $7.5 Million for Fourth Quarter of Fiscal 2014 Primarily Due to Accounting Treatment of Ruthigen Conference Call Begins at 4:30 p.m. PETALUMA, Calif.--(June 12, 2014)--Oculus Innovative Sciences,
Read more →SNOAOculus Innovative Sciences Reports Revenues of $3.3 Million for Third Quarter of Fiscal 2014 Microcyn Scar Management HydroGel Approved by FDA in U.S. and Ministry of Health in Mexico During Quarter
Oculus Innovative Sciences Reports Revenues of $3.3 Million for Third Quarter of Fiscal 2014 Conference Call Begins at 4:30 p.m. PETALUMA, Calif.--(February 13, 2014)--Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced financial results for the third quarter of f
Read more →SNOAOculus Innovative Sciences Reports Revenues of $4.1 Million for Second Quarter of Fiscal 2014, Meeting Guidance of Greater than $3.6 Million EBITDAS for second quarter was ($882,000), including $994
Oculus Innovative Sciences Reports Revenues of $4.1 Million for Second Quarter of Fiscal 2014, Meeting Guidance of Greater than $3.6 Million EBITDAS for second quarter was ($882,000), including $994,000 of Ruthigen-related expenses in the quarter, resulting in a positive EBITD
Read more →SNOAOculus Innovative Sciences Reports Revenues of $3.4 Million for First Quarter of Fiscal 2014 EBITDAS for first quarter was ($713,000), which includes $477,000 of Ruthigen-related expenses in the qua
Oculus Innovative Sciences Reports Revenues of $3.4 Million for First Quarter of Fiscal 2014 Conference Call Begins at 4:30 p.m. (EDT) PETALUMA, Calif.--(August 8, 2013)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the first quarter o
Read more →SNOAOculus Innovative Sciences, Inc. 1129 N. McDowell Blvd. Petaluma, California 94954 (707) 283-0550
Oculus Innovative Sciences, Inc. 1129 N. McDowell Blvd. Petaluma, California 94954 Dear Fellow Stockholder of Oculus Innovative Sciences, Inc.: a year of significant change at Oculus, change that I firmly believe will set the stage for the future growth and success of our c
Read more →SNOAOculus Innovative Sciences Reports Revenues of $15.5 Million for Fiscal Year 2013, Product Revenue up 23 Percent EBITDAS for fiscal 2013 improved by $1.8 million to ($1.5) million including $410,000
Oculus Innovative Sciences Reports Revenues of $15.5 Million for Fiscal Year 2013, Product Revenue up 23 Percent Conference Call Begins at 4:30 p.m. PETALUMA, Calif.--(June 13, 2013)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the fo
Read more →SNOAOculus Innovative Sciences Announces Two Key Agreements with Company's Subsidiary, Ruthigen, Inc. License and Supply Agreement and Shared Services Agreement are Entered Into PETALUMA, Calif. - (
Oculus Innovative Sciences Announces Two Key Agreements with Company's Subsidiary, Ruthigen, Inc. License and Supply Agreement and Shared Services Agreement are Entered Into PETALUMA, Calif. - (June 6, 2013) - Oculus Innovative Sciences (NASDAQ: OCLS) announced today that th
Read more →SNOAThe Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 This presentation includes forward - looking statements that are made pursuant to the "safe harbor" provisions of the Private Securitie
The Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 This presentation includes forward - looking statements that are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 . While these statements are
Read more →SNOAOculus Innovative Sciences Announces Proposed Public Offering of Common Stock and Intention to Repay Certain Indebtedness PETALUMA, Calif. - (
Oculus Innovative Sciences Announces Proposed Public Offering of Common Stock and Intention to Repay Certain Indebtedness PETALUMA, Calif. - (March 6, 2013) - Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced that it intends to offer for sale its common stock in
Read more →SNOAOculus Innovative Sciences Reports Revenues of $3.5 Million for the Third Quarter of Fiscal 2013 Oculus board of directors unanimously approved a plan to spin off the company's novel drug RUT58-60 a
Oculus Innovative Sciences Reports Revenues of $3.5 Million for the Third Quarter of Fiscal 2013 Conference Call Begins at 4:30 p.m. (ET) PETALUMA, Calif.--(February 13, 2013)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the third qua
Read more →SNOAOculus Innovative Sciences Achieves Net Worth of $4.5 Million Pro Forma as of
Oculus Innovative Sciences Achieves Net Worth of $4.5 Million Pro Forma as of September 30, 2012 and Regains Compliance with the Stockholders' Requirement of the NASDAQ Listing Rules Company Raises Stockholder Equity above Required Minimum Prior to Grace Period Deadline PETAL
Read more →SNOAOculus Innovative Sciences Reports Record Revenues of $4.5 Million for the Second Quarter of Fiscal 2013 Revenue for the second quarter of $4.5 million, up 24% Revenue for six months of $8.6 million
Oculus Innovative Sciences Reports Record Revenues of $4.5 Million for the Second Quarter of Fiscal 2013 Conference Call Begins at 4:30 p.m. (EDT) PETALUMA, Calif.--(November 1, 2012)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the s
Read more →SNOAOculus Innovative Sciences Reports Record Revenues of $4.1 Million for the First Quarter of Fiscal 2013 Revenue of $4.1 Million, up 38% U.S. Product Revenue up $1.2 Million or 142% High U.S. Growth
Oculus Innovative Sciences Reports Record Revenues of $4.1 Million for the First Quarter of Fiscal 2013 Conference Call Begins at 4:30 p.m. (EDT) PETALUMA, Calif. (August 2, 2012) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the firs
Read more →SNOAOculus Innovative Sciences Reports Fiscal Fourth Quarter 2012 Financial Results Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (
Oculus Innovative Sciences Reports Fiscal Fourth Quarter 2012 Financial Results Conference Call Begins at 4:30 p.m. PETALUMA, Calif. (June 7, 2012) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the fourth quarter of fiscal year 2012,
Read more →SNOAOculus Innovative Sciences Reports Fiscal Third Quarter 2012 Financial Results Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (
Oculus Innovative Sciences Reports Fiscal Third Quarter 2012 Financial Results Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (February 2, 2012) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the third quarter of fiscal
Read more →SNOAUnassociated Document FOR IMMEDIATE RELEASE Oculus Innovative Sciences Reports Record Fiscal Second Quarter 2012 Financial Results Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (
Oculus Innovative Sciences Reports Record Fiscal Second Quarter 2012 Financial Results Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (November 3, 2011) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the second quarter
Read more →SNOAUnassociated Document FOR IMMEDIATE RELEASE Oculus Innovative Sciences Reports Record First Quarter Financial Results Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (
Oculus Innovative Sciences Reports Record First Quarter Financial Results Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (August 4, 2011) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the first quarter of fiscal year 2
Read more →SNOAlogo.jpg] FOR IMMEDIATE RELEASE Oculus Innovative Sciences Reports Record Fourth Quarter, Beating Quarterly Guidance; and Reports Year-End Revenue for Fiscal Year Ended
Oculus Innovative Sciences Reports Record Fourth Quarter, Beating Quarterly Guidance; and Reports Year-End Revenue for Fiscal Year Ended March 31, 2011 Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (June 2, 2011) - Oculus Innovative Sciences, Inc. (Nasdaq: OC
Read more →SNOAUnassociated Document FOR IMMEDIATE RELEASE Oculus Innovative Sciences Reports Record Third Quarter Revenue for Fiscal Year 2011, Exceeding Guidance Q3 FY 2011 Results: Total Revenue of $2.3 Million Product Revenue Incre
Innovative Sciences Reports Record Third Quarter Revenue for Fiscal Year 2011, Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif. (February 3, 2011) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial and operating results for the third quarter of f
Read more →SNOAOculus Innovative Sciences Reports Record Revenue in Second Quarter Fiscal-Year 2011, Exceeding Guidance Q2 FY 2011 Results: Total Revenue of $2.5 Million Product Revenue Increased 63% Loss Narrows
Innovative Sciences Reports Record Revenue in Second Quarter 2011, Exceeding Guidance PETALUMA, Calif. (November 4, 2010) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial and operating results for the second quarter of fiscal year 2011, ended Septe
Read more →SNOAOculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2011 Q1 FY 2011 Milestones : Product Revenue Up 31% Over Q1 FY 2010 Operating Expenses Minus Non-Cash Expenses Down Slightly from Q1 F
Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2010/2011 Product Pipeline and Commercialization Plans: PETALUMA, Calif. (August 5, 2010) - Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial and operating results for the
Read more →SNOAOculus Innovative Sciences Reports FY 2010 Financial Results and Reviews Upcoming Microcyn Product Approvals and Introductions Q4 (January, February, March) FY 2010 Milestones : Revenue of $2.2 Million, Product Revenue G
Innovative Sciences Reports FY 2010 Financial Results and Reviews Microcyn Product Approvals and Introductions Q4 (January, February, March) FY 2010 Milestones: For Fiscal Year Ending March Upcoming International Expansion of Distribution from Eight EU Countries to 12 (201
Read more →SNOAOculus Innovative Sciences Reports FY 2009 Financial Results and Discusses Worldwide Revenue Growth Prospects Q4 FY 2009: Q4 2009 (Ending
Oculus Innovative Sciences Reports FY 2009 Financial Results and Discusses Worldwide Revenue Growth Prospects Q4 2009 (Ending March 31, 2009) Revenue of $1.5 Million, Up 59% over Q4 2008 Total FY 2009 Revenue of $5.4 million, Up 42% over FY 2008 Projected Q1 2010 (Ending
Read more →SNOAOculus Innovative Sciences Reports 59% Increase in First Quarter Product Revenue Conference Call Begins at 4:30 p.m. Eastern Time Today PETALUMA, Calif. (
Oculus Innovative Sciences Reports 59% Increase in First Quarter Product Revenue Conference Call Begins at 4:30 p.m. Eastern Time Today PETALUMA, Calif. (August 5, 2008) Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced financial and operating results for the fi
Read more →SNOAOculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update Recent Highlights o Filed patent on wound care device o Announced market assessme
Oculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update o Filed patent on wound care device o Announced market assessment of near-term commercialization opportunities for 510k cleared Dermacyn Wound Care in United
Read more →SNOAOCULUS INNOVATIVE SCIENCES, INC. ANNOUNCES $13.9
OCULUS INNOVATIVE SCIENCES, INC. ANNOUNCES $13.9 MILLION SECURITIES OFFERING PETALUMA, CA. March 28, 2008 Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced an offering to sell securities to selected institutional investors for aggregate gross proceeds of $13,926
Read more →SNOAOculus Innovative Sciences Announces Fiscal Third Quarter 2008 Quarterly Results and Clinical Update Highlights Completed patient treatment and follow-up in Microcyn Phase II clinical trial in mildl
Oculus Innovative Sciences Announces Fiscal Third Quarter 2008 Quarterly Results and Clinical Update Completed patient treatment and follow-up in Microcyn Phase II clinical trial in mildly infected diabetic foot ulcers Announced upcoming presentation of Microcyn Phase II
Read more →SNOAOculus Innovative Sciences Announces Fiscal First Quarter 2008 Financial Results PETALUMA, CA
Oculus Innovative Sciences Announces Fiscal First Quarter 2008 Financial Results PETALUMA, CA August 9, 2007 Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for its fiscal first quarter of 2008, ended June 30, 2007. Following the Company s IP
Read more →SNOAOculus Innovative Sciences Announces $10 Million Private Placement of Common Stock PETALUMA, CA. (
Oculus Innovative Sciences Announces $10 Million Private Placement of Common Stock PETALUMA, CA. (Aug. 8, 2007) Oculus Innovative Sciences (Nasdaq: OCLS) today announced that it has entered into definitive agreements with institutional and other accredited investors with respec
Read more →SNOAOculus Innovative Sciences Announces Fiscal Third Quarter 2007 Results PETALUMA, CA
Oculus Innovative Sciences Announces Fiscal Third Quarter 2007 Results CA February 22, 2007 Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced financial results for the fiscal third quarter ended December 31, 2006. Revenue for the three months ended December 31,
Read more →Competitive Position
How SNOA ranks across every disease it competes inCompetitive Position is a premium feature
See how SNOA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial